Member Info for Laura2022

Spoken with them

I asked about the use of the word, they say they cannot give numbers as there us a non disclosure (?) But the word was used to depict the size and scope compared to previous revenues . They said they may be able to say more in the annual report when they discuss the current financial year.

They said Bicycle are a very good client and expect this to grow

Hope that helps

L

Eagle

I would imagine more newsflow based on the last few RNSs

Thabkyou Ralph

In that case that was a quick contract win ?

The limits have been cut down today , approximately 800,000 shares on HL then they won't allow more to buy

How much could the DoseMeRx potential deal be worth to PYC ?

The Company is actively exploring non-dilutional grant funding opportunities for all its personalised dosing initiatives and if successful these could provide additional sources of funding in FY24

o  Collaboration with DoseMe - the Company is in an ongoing dialogue with the new management of DoseMe and further announcements on this will be made in due course

Superb spot Kidlington

You are right..the use of funds was for GROWTH areas such as bio statistics ( basically FDA computer modelling so data has been fully embedded into drug programmes )

As far as we know PYC is uniquely positioned to help companies adhere to (and get approval from) FDA rules on mew and existing drug programmes.

That has to worth £££s in business going forward?

9 May 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Publication of article in Frontiers in Oncology

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, is pleased to announce the publication of an original article "Should personalised dosing have a role in cancer treatment?" in a special edition of the journal "Frontiers in Oncology" focused on the FDA's Project Optimus.

 

Let's see what today brings

Well spotted Kidlington regarding project optimus and FDA , I think it was yourself that found a link to the $250mln bicycle fund raise please ?

PM

Notice also the plural use of program(s) AND the first use of the word "substantial" which PYC have never quantifie before.

Bicycle and Cellcentric (2 key long term clients) have recently raised $250mln and £25mln respectively

I would imagine PYC will stand to benefit

At £1.4mln cap with £800k cash (including the £380k raised in June) and so many growth opportunities PYC looks severely undervalued

These will be under NDA hence no ££value BUT Bicycle just raised $250mln just a month ago, maybe Bicycle could just buy PYC in a takeover eventually if we are doing so much work for their drug pipeline ?

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics ("Bicycle") that it expects to be completed over the next six months.  The project involves modelling and the use of bioinformatics data in support of target identification for undisclosed Bicycle programs.

 

Physiomics CEO, Dr Jim Millen, commented: "We are delighted that, having worked on a number of clinical stage projects with Bicycle, we are now complementing these with a substantial project focused on earlier stage drug development.  We look forward to working once again with Bicycle's talented team

Sienna

The first few lines make no sense whatsoever,if you have bought you are surely happy that your investment is based on your research ?

Hard to buy

Spread is 1.9 to 2.3 Gordon

Someone is definitely stake building in APTA gents

Thats now the 5th or 6th delayed buy in last 3 days

Huge buy appeared from the morning as suggested

Even a small fraction of this market would be a big deal to APTA

Now

Good to see from 10 pence